| Serial Number | 79402612 |
| Word Mark | CARSGEN |
| Filing Date | Tuesday, April 9, 2024 |
| Status | 686 - PUBLISHED FOR OPPOSITION |
| Status Date | Tuesday, October 21, 2025 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 5 - Drawing with word(s) / letter(s) / number(s) in Stylized form |
| Published for Opposition Date | Tuesday, October 21, 2025 |
| Goods and Services | Medical screening; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; human tissue bank services; alternative medicine services; therapy services, namely, medical therapy, medicine therapy, immunotherapy, cell therapy, gene therapy, antibody therapy, antibody-drug conjugate therapy, radiation therapy, chemotherapy, and stem cell therapy; telemedicine services; health care; medical clinic services |
| Goods and Services | Pharmaceutical preparations for the treatment of tumors, cancer, autoimmune diseases or disorders, inflammatory diseases, cardiovascular diseases, digestive system diseases, diabetes mellitus, endocrine and metabolic diseases, chronic respiratory diseases, nervous system diseases, bone and joint diseases, mental and psychological diseases, chronic kidney diseases, eye and ear diseases, congenital genetic cardiovascular and neurological diseases, infectious diseases, immune system related diseases and disorders, and blood diseases; drugs for medical purposes, namely, pharmaceutical preparations for the treatment of tumors, cancer, autoimmune diseases or disorders, inflammatory diseases, cardiovascular diseases, digestive system diseases, diabetes mellitus, endocrine and metabolic diseases, chronic respiratory diseases, nervous system diseases, bone and joint diseases, mental and psychological diseases, chronic kidney diseases, eye and ear diseases, congenital genetic cardiovascular and neurological diseases, infectious diseases, immune system related diseases and disorders, and blood diseases; biological preparations for medical purposes for the treatment of tumors, cancer, autoimmune diseases or disorders, inflammatory diseases, cardiovascular diseases, digestive system diseases, diabetes mellitus, endocrine and metabolic diseases, chronic respiratory diseases, nervous system diseases, bone and joint diseases, mental and psychological diseases, chronic kidney diseases, eye and ear diseases, congenital genetic cardiovascular and neurological diseases, infectious diseases, immune system related diseases and disorders, and blood diseases; medicinal solutions for injection, namely, medicines for the treatment of tumors, cancer, autoimmune diseases or disorders, inflammatory diseases, cardiovascular diseases, digestive system diseases, diabetes mellitus, endocrine and metabolic diseases, chronic respiratory diseases, nervous system diseases, bone and joint diseases, mental and psychological diseases, chronic kidney diseases, eye and ear diseases, congenital genetic cardiovascular and neurological diseases, infectious diseases, immune system related diseases and disorders, and blood diseases; biomedicine for the treatment of tumors, cancer, autoimmune diseases or disorders, inflammatory diseases, cardiovascular diseases, digestive system diseases, diabetes mellitus, endocrine and metabolic diseases, chronic respiratory diseases, nervous system diseases, bone and joint diseases, mental and psychological diseases, chronic kidney diseases, eye and ear diseases, congenital genetic cardiovascular and neurological diseases, infectious diseases, immune system related diseases and disorders, and blood diseases; blood for medical purposes; pre-filled syringes for medical purposes filled with pharmaceutical preparations for the treatment of tumors, cancer, autoimmune diseases or disorders, inflammatory diseases, cardiovascular diseases, digestive system diseases, diabetes mellitus, endocrine and metabolic diseases, chronic respiratory diseases, nervous system diseases, bone and joint diseases, mental and psychological diseases, chronic kidney diseases, eye and ear diseases, congenital genetic cardiovascular and neurological diseases, infectious diseases, immune system related diseases and disorders, and blood diseases; diagnostic preparations for medical purposes; diagnostic biomarker reagents for medical purposes; pharmaceuticals for the treatment of tumors, cancer, autoimmune diseases or disorders, inflammatory diseases, cardiovascular diseases, digestive system diseases, diabetes mellitus, endocrine and metabolic diseases, chronic respiratory diseases, nervous system diseases, bone and joint diseases, mental and psychological diseases, chronic kidney diseases, eye and ear diseases, congenital genetic cardiovascular and neurological diseases, infectious diseases, immune system related diseases and disorders, and blood diseases; biological tissue cultures for medical purposes; serotherapeutic medicines for the treatment of tumors, cancer, autoimmune diseases or disorders, inflammatory diseases, cardiovascular diseases, digestive system diseases, diabetes mellitus, endocrine and metabolic diseases, chronic respiratory diseases, nervous system diseases, bone and joint diseases, mental and psychological diseases, chronic kidney diseases, eye and ear diseases, congenital genetic cardiovascular and neurological diseases, infectious diseases, immune system related diseases and disorders, and blood diseases |
| Goods and Services | Scientific research; scientific laboratory services; research and development of new products for others; technical project studies, namely, conducting scientific feasibility studies; technological research in the field of pharmaceutical studies, biotechnology, medicine, immunotherapy; chemical research; chemistry services, namely, chemist services and chemistry consultation; chemical analysis; medical research; medical and scientific research, namely, conducting clinical trials for others; biological research |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, August 22, 2024 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, August 22, 2024 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, August 22, 2024 |
| Primary Code | 044 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | CARsgen Therapeutics Co., Ltd |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 99 - Other |
| Address | CN |
| Party Name | CARsgen Therapeutics Co., Ltd |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 99 - Other |
| Address | CN |
| Event Date | Event Description |
| Thursday, August 22, 2024 | SN ASSIGNED FOR SECT 66A APPL FROM IB |
| Friday, August 23, 2024 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Friday, August 23, 2024 | APPLICATION FILING RECEIPT MAILED |
| Tuesday, October 22, 2024 | ASSIGNED TO EXAMINER |
| Tuesday, October 22, 2024 | NON-FINAL ACTION WRITTEN |
| Wednesday, October 23, 2024 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Tuesday, October 29, 2024 | REFUSAL PROCESSED BY MPU |
| Tuesday, October 29, 2024 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Sunday, November 17, 2024 | REFUSAL PROCESSED BY IB |
| Tuesday, April 1, 2025 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Tuesday, April 1, 2025 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Tuesday, April 1, 2025 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Tuesday, April 1, 2025 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Tuesday, April 1, 2025 | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS |
| Tuesday, April 1, 2025 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Wednesday, April 2, 2025 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Wednesday, April 2, 2025 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Wednesday, April 2, 2025 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Friday, April 4, 2025 | FINAL REFUSAL WRITTEN |
| Friday, April 4, 2025 | FINAL REFUSAL E-MAILED |
| Friday, April 4, 2025 | NOTIFICATION OF FINAL REFUSAL EMAILED |
| Tuesday, September 23, 2025 | EXAMINERS AMENDMENT -WRITTEN |
| Tuesday, September 23, 2025 | EXAMINERS AMENDMENT E-MAILED |
| Tuesday, September 23, 2025 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Tuesday, September 23, 2025 | EXAMINER'S AMENDMENT ENTERED |
| Tuesday, September 23, 2025 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, October 15, 2025 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, October 21, 2025 | PUBLISHED FOR OPPOSITION |
| Tuesday, October 21, 2025 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |